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Summary
Background Peginterferon plus ribavirin achieves sustained virological response (SVR) in fewer than half of patients 
with genotype 1 chronic hepatitis C virus infection treated for 48 weeks. We tested the eﬃ  cacy of boceprevir, an NS3 
hepatitis C virus oral protease inhibitor, when added to peginterferon alfa-2b and ribavirin.
Methods In part 1 of this trial, undertaken in 67 sites in the USA, Canada, and Europe, 520 treatment-naive patients 
with genotype 1 hepatitis C virus infection were randomly assigned to receive peginterferon alfa-2b 1·5 μg/kg plus 
ribavirin 800–1400 mg daily for 48 weeks (PR48; n=104); peginterferon alfa-2b and ribavirin daily for 4 weeks, followed 
by peginterferon alfa-2b, ribavirin, and boceprevir 800 mg three times a day for 24 weeks (PR4/PRB24; n=103) or 
44 weeks (PR4/PRB44; n=103); or peginterferon alfa-2b, ribavirin, and boceprevir three times a day for 28 weeks (PRB28; 
n=107) or 48 weeks (PRB48; n=103). In part 2, 75 patients were randomly assigned to receive either PRB48 (n=16) or 
low-dose ribavirin (400–1000 mg) plus peginterferon alfa-2b and boceprevir three times a day for 48 weeks (low-dose 
PRB48; n=59). Randomisation was by computer-generated code, and study personnel and patients were not masked 
to group assignment. The primary endpoint was SVR 24 weeks after treatment. Analysis was by intention to treat. 
This study is registered with ClinicalTrials.gov, number NCT00423670.
Findings Patients in all four boceprevir groups had higher rates of SVR than did the control group (58/107 [54%, 
95% CI 44–64], p=0·013 for PRB28; 58/103 [56%, 44–66], p=0·005 for PR4/PRB24; 69/103 [67%, 57–76], p<0·0001 
for PRB48; and 77/103 [75%, 65–83], p<0·0001 for PR4/PRB44; vs 39/104 [38%, 28–48] for PR48 control). Low-
dose ribavirin was associated with a high rate of viral breakthrough (16/59 [27%]), and a rate of relapse (six of 
27 [22%]) similar to control (12/51 [24%]). Boceprevir-based groups had higher rates of anaemia (227/416 [55%] 
vs 35/104 [34%]) and dysgeusia (111/416 [27%] vs nine of 104 [9%]) than did the control group.
Interpretation In patients with untreated genotype 1 chronic hepatitis C infection, the addition of the direct-acting 
antiviral agent boceprevir to standard treatment with peginterferon and ribavirin after a 4-week lead-in seems to have 
the potential to double the sustained response rate compared with that recorded with standard treatment alone.
Funding Merck.
Introduction
Chronic hepatitis C virus aﬀ ects about 170 million people 
worldwide. Cirrhosis induced by hepatitis C virus is the 
most common indication for liver transplantation and is 
a major contributor to the worldwide increase in the 
incidence of hepatocellular cancer.1,2 Standard-of-care 
treatment of genotype 1 hepatitis C virus is pegylated 
interferon and ribavirin for 48 weeks, which results in 
sustained virological response (SVR) in about 40–50% of 
individuals.3–5 SVR rates for black patients treated with 
standard of care are substantially lower; in two studies 
undertaken almost exclusively in genotype 1 individuals, 
19–28% of black people achieved SVR versus 52% of 
non-Hispanic white people.6,7 Those who achieve SVR 
can have long-term beneﬁ ts with improvement in 
degrees of liver ﬁ brosis, reduction in complications of 
chronic liver disease, and improved quality of life.8 
Studies have shown that response-guided therapy can 
allow tailoring of duration of treatment, with week 4 
viral clearance (rapid virological response) allowing 
shorter duration of therapy than for those who clear 
virus at week 12 (complete early virological response).9–12
Up until now, treatment for this disease has consisted of 
therapies to stimulate the immune system and interfere in 
a non-speciﬁ c manner with viral replication. Research has 
focussed on therapies that inhibit hepatitis C virus proteins 
that are essential for intracellular replication; these drugs 
are referred to as direct-acting antiviral agents.13 Boceprevir 
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is a novel peptidomimetic NS3 protease inhibitor that 
forms a covalent reversible complex with the NS3 protease 
in vitro and has shown potent antiviral activity in the 
hepatitis C virus replicon system, and in patients who 
previously showed no response to peginterferon 
administered with or without ribavirin.14,15 In a dose-
ascending study in null responders,16 boceprevir, when 
given in combination with peginterferon alfa-2b and 
ribavirin, was associated with a modest incremental 
haemoglobin reduction, as has been recorded with other 
direct-acting antiviral agents in the NS3 inhibitor class.17,18 
The NS3 protease inhibitor telaprevir has also shown 
signiﬁ cantly higher rates of SVR than has standard of care 
in patients with genotype 1 disease when given for 12 weeks 
in combination with regimens of peginterferon and 
ribavirin lasting 12, 24, or 48 weeks.17,18 Although rates of 
SVR in the telaprevir groups were higher than were those 
recorded with standard of care, investigators noted higher 
drop-out rates due to increased side-eﬀ ects.
The aim of the hepatitis C virus SPRINT-1 (Serine 
Protease Inhibitor Therapy-1) study was to establish the 
safety and eﬃ  cacy of boceprevir when added to 
peginterferon and ribavirin. We investigated treatment 
durations of 28 weeks versus 48 weeks, with and without a 
4-week lead-in of peginterferon alfa-2b and ribavirin 
before the addition of boceprevir for 24 or 44 weeks, and 
the eﬃ  cacy of low-dose ribavirin. The rationale for the 
4-week lead-in was to allow pegylated interferon and 
ribavirin to reach steady-state concentrations before the 
addition of boceprevir such that backbone drug 
concentrations would be at an optimum and potentially 
reduce the likelihood for emergence of drug-resistant 
mutations by reducing viral levels.19~21 Part 2 of this study, 
which was added after enrolment in part 1 was completed, 
was undertaken to assess the possibility of use of a lower 
dose of ribavirin to reduce treatment complications, 
mainly anaemia. Since boceprevir and other NS3 protease 
inhibitors have been associated with a modest reduction 
in haemoglobin, weight-based low-dose (400–1000 mg per 
day) versus standard-dose (800–1400 mg per day) ribavirin 
was assessed to establish whether eﬃ  cacy could be 
maintained while reducing anaemia. Lastly, we examined 
the rates of viral clearance and SVR.
Methods
Study design and participants
This was an open-label, randomised trial undertaken in 
hospitals in the USA, Canada, and Europe. Study 
enrolment began in January, 2007, and data collection 
concluded in November, 2008. Covance Central Laboratory 
Services in both Indianapolis, IN, USA, and Meyrin 
Geneva, Switzerland, were used as the contracted central 
laboratories for this study. Previously untreated adults with 
genotype 1 hepatitis C virus infection, aged 18–60 years 
were eligible to be enrolled. Liver biopsy consistent with 
chronic hepatitis C virus infection within 5 years of 
enrolment was required. Minimum haematological and 
biochemical parameters included haemoglobin of 130 g/L 
in men and 120 g/L in women, neutrophil count 1·5×10⁹/L, 
platelet count 100×10⁹/L, and bilirubin, albumin, and 
creatinine within normal limits. Patients with a 
documented history of any of the following were excluded: 
decompensated cirrhosis, HIV infection, previous organ 
transplantation, other causes of liver disease, pre-existing 
psychiatric disease, seizure disorder, cardiovascular 
disease, haemo globinopathies, haemophilia, poorly 
controlled diabetes, and autoimmune disease.
Before the start of the study, the study protocol and 
informed consent form were reviewed and approved by 
an institutional review board or ethics committee. We 
obtained written informed consent from all patients 
before any study-related activity was done; the study was 
undertaken in accordance with provisions of the 
Declaration of Helsinki and Good Clinical Practice 
guidelines. A Data Review Advisory Board met twice a 
year to monitor the progress of the study and review 
safety data. The board was to provide recommendations 
for stopping the study and modifying its design according 
to the guidance provided in the protocol. The committee 
included at least three members not employed by the 
sponsor (including one outside statistician and the 
committee’s chairperson), who were not involved in the 
conduct of the study. None of the sponsor committee 
members had voting privileges.
Randomisation and masking
For part 1 of the study, patients were randomly assigned 
to one of the ﬁ ve treatment groups in a 1:1:1:1:1 ratio. 
Randomised treatment assignment was stratiﬁ ed by race 
(black vs non-black, self-reported) and cirrhosis status 
(cirrhosis vs no cirrhosis, on the basis of local pathology 
results). The sponsor’s biostatistics department provided 
a computer generated random code to the external 
Central Randomization Center (Covance IVRS, Princeton, 
NJ, USA) to implement the randomisation. Once a 
prospective participant was determined to be eligible for 
the study, the site called the centre to obtain a patient 
number and treatment assignment for the participant.
For part 2, participants were randomly assigned in a 
1:4 ratio to the standard ribavirin dose group or the lower 
ribavirin dose group, respectively, and there was no 
stratiﬁ cation. Implementation procedures were the same 
as for part 1. Participants, those giving the interventions, 
those assessing outcomes, and those analysing the data 
were not masked to group assignment. 
Procedures
The study had seven treatment groups, which were 
grouped into two parts (ﬁ gure 1). Part 1 consisted of ﬁ ve 
treatment groups: one was a control group in which 
patients received peginterferon alfa-2b 1·5 μg/kg plus 
ribavirin 800–1400 mg per day for 48 weeks (PR48). Two 
groups, the lead-in groups, received peginterferon alfa-2b 
1·5 μg/kg and ribavirin 800–1400 mg daily for 4 weeks 
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(PR4), followed by peginterferon alfa-2b, ribavirin, and 
boceprevir 800 mg three times a day for 24 weeks (PRB24) 
or 44 weeks (PRB44). The last two groups of part 1 
received peginterferon alfa-2b 1·5 μg/kg, ribavirin 
800–1400 mg, and boceprevir 800 mg three times a day 
for 28 weeks (PRB28) or 48 weeks (PRB48). Part 2, in 
which participants were enrolled separately, consisted of 
two groups: one received PRB48 and served as a control 
for the last group, which explored the safety and eﬃ  cacy 
of low-dose ribavirin (400–1000 mg) plus peginterferon 
alfa-2b 1·5 μg/kg and boceprevir 800 mg three times a 
day for 48 weeks (low-dose PRB48).
The dosing for ribavirin was weight based: patients 
weighing 65 kg and less received 800 mg per day (400 mg 
twice daily), those weighing 66–80 kg received 1000 mg 
per day (400 mg in the morning and 600 in the evening), 
those weighing 81–105 kg received 1200 mg per day 
(600 mg twice daily), and those weighing more than 
105 kg received 1400 mg per day (600 mg in the morning 
and 800 in the evening).
Adverse events were graded as mild, moderate, and 
severe or potentially life-threatening. Dependent on the 
severity of an adverse event that was deemed by the 
investigator to be related to peginterferon alfa-2b, the drug 
could be discontinued permanently, held for up to 2 weeks, 
or dose-reduced with a two-step reduction from 1·5 μg/kg 
to 1·0 μg/kg, and then to 0·5 μg/kg. For anaemia, the 
ribavirin dose was lowered by 200 mg per day apart from 
in the 1400 mg group when the initial reduction was 
400 mg per day. Dose reduction of boceprevir was by 
200 mg per dose to 600 mg three times a day, and again to 
400 mg three times a day at the discretion of the investigator. 
Anaemia, deﬁ ned as haemoglobin less than 100 g/L, was 
managed with protocol-recommended guidelines for 
ribavirin dose reduction. At the discretion of the 
investigator, use of epoetin alfa was allowed with 
concomitant ribavirin dose reduction.
The primary eﬃ  cacy endpoint was SVR, deﬁ ned as the 
proportion of patients with undetectable hepatitis C virus 
RNA (Roche Cobas TaqMan with lower limit of detection 
of 15 IU/mL) 24 weeks after discontinuation of therapy. 
Genotype was measured with the TruGene assay (Bayer 
HealthCare, Berkeley, CA, USA). Viral breakthrough was 
deﬁ ned as a 2 log10 increase of hepatitis C virus RNA 
from nadir detected on two consecutive measurements 
with a quantitative concentration of 50 000 IU/mL or 
more. Mutations were assessed by population sequencing 
of the NS3 domain.
Statistical analysis
All inferential eﬃ  cacy analyses were based on patients 
randomly assigned and treated in groups 1–5 in part 1 of 
the study. With 80 patients in each group, the study had 
80% power to detect a 22% diﬀ erence in SVR between 
the control group and any of the four boceprevir groups 
(α=0·05, two-sided test), assuming an SVR rate for 
control of 50% (ie, 72% vs 50%). Part 2, which included a 
diﬀ erent cohort of patients from selected sites who were 
enrolled later and were assigned to drug treatment with a 
separate randomisation schedule, was designed to assess 
the PRB48 low-dose ribavirin regimen.
The primary statistical analysis for the primary 
endpoint was done with the Cochran-Mantel Haenszel χ² 
test to compare the four boceprevir groups with control, 
adjusting for the baseline stratiﬁ cation factors, race 
(black vs non-black) and cirrhosis status (yes vs no). Since 
there were multiple treatment groups, a step-down 
approach was prespeciﬁ ed in the statistical hypothesis 
testing procedure to maintain the overall type-1 error rate 
at α=0·05. First, PR4/PRB44 was compared with control 
with respect to SVR, and if this test was signiﬁ cant 
(p<0·05), PRB48 was to be compared with control. If this 
comparison was also signiﬁ cant, PR4/PRB24 was to be 
compared with control, and if signiﬁ cant, PRB28 was to 
be compared with control. At any point, a non-signiﬁ cant 
result (p>0·05) would preclude further testing.
All assays to establish concentrations of hepatitis C 
virus RNA for all participants throughout the study were 
done in a masked manner by an independent commercial 
laboratory that did not have access to participant treatment 
assignments. The primary and other key study endpoints 
were based on concentration of hepatitis C virus RNA, 
which is an outcome that is not subject to bias.22
Figure 1: Trial design
Patients in all groups were followed up for 24 weeks after the end of treatment. PR4 (lead-in)=peginterferon 
alfa-2b 1·5 μg/kg plus ribavirin 800–1400 mg per day for 4 weeks. PR48 (control)=peginterferon alfa-2b 1·5 μg/kg 
plus ribavirin 800–1400 mg per day for 48 weeks. PRB24/28/44/48=peginterferon alfa-2b, ribavirin, and 
boceprevir 800 mg three times a day for 24, 28, 44, or 48 weeks. Low-dose PRB48=peginterferon alfa-2b, ribavirin 
400–1000 mg, and boceprevir 800 mg three times a day for 48 weeks.
PR48 Peginterferon alfa-2b 1·5 μg/kg+
ribavirin 800–1400 mg per day
24-week
follow-up
PR4/PRB24 Lead-in
Peginterferon alfa-2b 1·5 μg/kg+
ribavirin 800–1400 mg per day+
boceprevir 800 mg three times per day
24-week
follow-up
PR4/PRB44
Peginterferon alfa-2b 1·5 μg/kg+
ribavirin 800–1400 mg per day+
boceprevir 800 mg three times per day
24-week
follow-up
PRB28
Peginterferon alfa-2b 1·5 μg/kg+
ribavirin 800–1400 mg per day+
boceprevir 800 mg three times per day
24-week
follow-up
PRB48 24-week
follow-up
PRB48 24-week
follow-up
Low-dose
PRB48
24-week
follow-up
Lead-in
Peginterferon alfa-2b 1·5 μg/kg+
ribavirin 800–1400 mg per day+
boceprevir 800 mg three times per day
Peginterferon alfa-2b 1·5 μg/kg+
ribavirin 800–1400 mg per day+
boceprevir 800 mg three times per day
Peginterferon alfa-2b 1·5 μg/kg+
ribavirin 400–1000 mg per day+
boceprevir 800 mg three times per day
Part 1
Part 2
Week 4 Week 28 Week 48
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Exact two-sided 95% CIs for the SVR rate were 
calculated for each treatment group, whereas 95 % CIs 
for the diﬀ erence between each boceprevir group (in 
part 1) and control (PR48 group) were based on a normal 
approximation. Nominal p values for each boceprevir 
group versus control were calculated for end of treatment 
(χ² test), SVR (Cochran-Mantel-Haenszel adjusted χ² 
test), and viral breakthrough (Fisher’s exact test).
To assess the eﬀ ect of the 4-week lead-in on SVR, the 
pooled rate from the PRB28 and PRB48 groups was 
compared with the pooled rate from the PR4/PRB24 and 
PR4/PRB44 groups. Similarly, to assess the eﬀ ect of 
treatment duration on SVR, the pooled rate from the 
28-week groups was compared with the pooled rate from 
the 48-week groups.
The relation between rapid virological response, based 
on week 4 of boceprevir therapy (treatment week 8 in the 
groups with 4-week lead in) and SVR was summarised 
with the proportion of patients who achieved SVR in 
patients with concentrations of hepatitis C virus RNA 
below the lower limit of detection at week 4 of boceprevir 
therapy. Similarly, the relation between viral clearance 
between weeks 4 and 12 of boceprevir (treatment weeks 
8–16 in the lead-in groups) and SVR was summarised with 
the proportion of patients achieving SVR in those with 
concentrations of hepatitis C virus RNA below the lower 
limit of detection for the ﬁ rst time between weeks 4 and 12 
of boceprevir therapy. Although comparisons among the 
treatment groups with respect to relapse rates were not 
randomised comparisons, nominal p values (based on 
two-sided χ² tests) were calculated.
SVR was also summarised for important subpopulations 
of patients on the basis of prespeciﬁ ed baseline demographic 
and disease characteristics (identiﬁ ed in previous studies of 
patients with hepatitis C virus treated with peginterferon 
alfa-2b plus ribavirin). For each subpopulation, the odds 
ratio and 95% CI for the treatment eﬀ ect of PR4/PRB44 
versus PR48 (control) was obtained from a logistic 
regression analysis of SVR on treatment, with adjustment 
for the stratiﬁ cation factors (race and cirrhosis status). 
Finally, data from the four boceprevir groups were 
combined, and a multivariable logistic regression analysis 
of SVR was done, with treatment and the baseline factors 
included as potential prognostic factors. A stepwise 
procedure was used to identify independent predictors of 
SVR (with p=0·05 as the threshold for variables to be 
entered and retained in the ﬁ nal model).
Additionally, we examined the associations between the 
development of anaemia, use of epoetin alfa, and SVR. 
Since the rate of study discontinuation was fairly high, 
each boceprevir group was compared with control with 
respect to the discontinuation rate (two-sided χ² test).
This trial is registered with ClinicalTrials.gov, number 
NCT00423670.
Part 1 Part 2
PR48 
(n=104)
PR4/PRB24 
(n=103)
PR4/PRB44 
(n=103)
PRB28 
(n=107)
PRB48 
(n=103)
PRB48 
(n=16)
Low-dose PRB48 
(n=59)
Sex
Women 34 (33%) 52 (50%) 45 (44%) 44 (41%) 40 (39%) 7 (44%) 18 (31%)
Men 70 (67%) 51 (50%) 58 (56%) 63 (59%) 63 (61%) 9 (56%) 41 (69%)
Race
White 83 (80%) 85 (83%) 85 (83%) 86 (80%) 87 (84%) 12 (75%) 43 (73%)
Non-white 21 (20%) 18 (17%) 18 (17%) 21 (20%) 16 (16%) 4 (25%) 16 (27%)
American Indian or Alaskan 2 (2%) 1 (1%) 1 (1%) 0 0 0 0
Asian 3 (3%) 1 (1%) 2 (2%) 2 (2%) 1 (1%) 0 0
Black 16 (15%) 15 (15%) 15 (15%) 18 (17%) 14 (14%) 4 (25%) 16 (27%)
Multiracial 0 1 (1%) 0 1 (1%) 1 (1%) 0 0
Age (years) 48·3 (6·9) 47·7 (7·4) 47·6 (8·3) 46·4 (8·0) 46·7 (8·8) 50·3 (8·5) 48·7 (5·8)
Weight (kg) 83·4 (16·2) 79·9 (14·2) 78·4 (16·5) 83·4 (17·3) 80·0 (19·4) 81·4 (12·9) 88·5 (19·9)
HCV genotype
1a 53 (51%) 53 (51%) 60 (58%) 67 (63%) 55 (53%) 7 (44%) 39 (66%)
1b 42 (40%) 37 (36%) 35 (34%) 30 (28%) 36 (35%) 7 (44%) 18 (31%)
1 (no subtype) 9 (9%) 13 (13%) 8 (8%) 10 (9%) 12 (12%) 2 (13%) 2 (3%)
Baseline HCV RNA 
Log10 of geometric mean 6·53 6·53 6·53 6·64 6·54 6·43 6·47
>600 000 IU/mL 94 (90%) 90 (87%) 93 (90%) 98 (92%) 94 (91%) 13 (81%) 49 (83%)
Cirrhosis 8 (8%) 7 (7%) 6 (6%) 7 (7%) 9 (9%) 0 4 (7%)
Data are number (%) or mean (SD), unless otherwise indicated. PR4 (lead-in)=peginterferon alfa-2b 1·5 μg/kg plus ribavirin 800−1400 mg per day for 4 weeks. 
PR48 (control)=peginterferon alfa-2b 1·5 μg/kg plus ribavirin 800−1400 mg per day for 48 weeks. PRB24/28/44/48=peginterferon alfa-2b, ribavirin, and boceprevir 800 mg three 
times a day for 24, 28, 44, or 48 weeks. Low-dose PRB48=peginterferon alfa-2b, ribavirin 400–1000 mg, and boceprevir 800 mg three times a day for 48 weeks. HCV=hepatitis C virus. 
Table 1: Baseline demographics and disease characteristics
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Role of the funding source
The sponsor of the study contributed to patient 
recruitment, trial management, data collection, statistical 
analyses, and the writing and review of the report. The 
corresponding author had full access to all the data in the 
study and had ﬁ nal responsibility for the decision to 
submit for publication.
Results
765 patients were screened and 595 were enrolled in 43 US, 
four Canadian, and 20 European Union sites. All eﬃ  cacy 
and safety analyses were based on 595 patients who were 
randomly assigned and received at least one dose of 
medication. Table 1 shows baseline characteristics, and 
ﬁ gures 2 and 3 show patient disposition for all groups.
Table 2 shows virological response. Irrespective of 
treatment duration or use of PR4 as lead-in, SVR rates in 
all four boceprevir groups in part 1 were signiﬁ cantly better 
than were those in the PR48 control group. In the 28-week 
treatment groups, the SVR was 56% (95% CI 46–66) in the 
PR4/PRB24 group (p=0·005 vs control) and 54% (44–64) in 
the PRB28 group (p=0·013 vs control). In the 48-week 
treatment groups, the SVR was 75% (65–83) in the PR4/
PRB44 group (p<0·0001 vs control) compared with 67% 
(57–76) in the PRB48 group (p<0·0001 vs control). In part 2, 
the SVR for low-dose PRB48 was 36% (24–49). 
We noted signiﬁ cantly lower relapse rates in the 
48-week treatment groups compared with PR48 control 
(PRB48, p=0·0079; PR4/PRB44, p=0·0002; table 2). 
Although the relapse rates were higher in the 28-week 
than in the 48-week treatment groups, patients in the 
28-week groups who had rapid hepatitis C virus RNA 
clearance at week 4 of boceprevir had substantially lower 
relapse rates than did those who did not have rapid viral 
Figure 2: Trial proﬁ le for part 1 of the study
PR4 (lead-in)=peginterferon alfa-2b 1·5 μg/kg plus ribavirin 800−1400 mg per day for 4 weeks. PR48 (control)=peginterferon alfa-2b 1·5 μg/kg plus ribavirin 800–1400 mg per day for 48 weeks. 
PRB24/28/44/48=peginterferon alfa-2b, ribavirin, and boceprevir 800 mg three times a day for 24, 28, 44, or 48 weeks.
104 assigned to PR48
104 treated
52 completed treatment phase
52 discontinued treatment
8 adverse event
36 protocol-deﬁned clinical
event
2 lost to follow-up
3 did not wish to continue
3 non-compliance with
protocol
97 entered follow-up
94 completed follow-up
3 discontinued follow-up
0 lost to follow-up
1 did not wish to continue
2 non-compliance with protocol
7 never entered follow-up
103 assigned to PR4/PRB24
103 treated
76 completed treatment phase
27 discontinued treatment
15 adverse event
4 protocol-deﬁned clinical
event
3 lost to follow-up
4 did not wish to continue
1 non-compliance with
protocol
96 entered follow-up
85 completed follow-up
11 discontinued follow-up
8 lost to follow-up
2 did not wish to continue
1 non-compliance with protocol
7 never entered follow-up
103 assigned to PR4/PRB44
103 treated
76 completed treatment phase
27 discontinued treatment
9 adverse event
5 protocol-deﬁned clinical
event
6 lost to follow-up
5 did not wish to continue
2 non-compliance with
protocol
91 entered follow-up
89 completed follow-up
2 discontinued follow-up
1 lost to follow-up
1 did not wish to continue
0 non-compliance with protocol
12 never entered follow-up
107 assigned to PRB28
107 treated
77 completed treatment phase
30 discontinued treatment
12 adverse event
7 protocol-deﬁned clinical
event
1 lost to follow-up
9 did not wish to continue
1 non-compliance with
protocol
100 entered follow-up
84 completed follow-up
16 discontinued follow-up
12 lost to follow-up
4 did not wish to continue
0 non-compliance with protocol
7 never entered follow-up
103 assigned to PRB48
103 treated
63 completed treatment phase
40 discontinued treatment
20 adverse event
12 protocol-deﬁned clinical
event
1 lost to follow-up
4 did not wish to continue
3 non-compliance with
protocol
96 entered follow-up
91 completed follow-up
5 discontinued follow-up
3 lost to follow-up
1 did not wish to continue
1 non-compliance with protocol
7 never entered follow-up
520 treated
598 randomised
765 screened 167 screened but not randomised
7 lost to follow-up
35 did not wish to continue
2 non-compliance with protocol
123 did not meet protocol eligibility
3 randomised but not treated
75 treated in part 2
Articles
710 www.thelancet.com   Vol 376   August 28, 2010
clearance (p<0·0001; table 2). Low-dose PRB was 
associated with high relapse rates. Of note, we recorded 
no viral breakthrough in control groups that did not 
contain boceprevir (table 2). In the boceprevir groups, 
the lead-in groups were associated with a modestly lower 
rate of breakthrough than were the groups with no lead 
in. Combining across treatment groups, the rate of 
breakthrough in the boceprevir lead-in groups was 4% 
(nine of 206) compared with 9% (19/210) in the boceprevir 
groups with no lead in (p=0·057). By population 
sequencing, the major mutations (in >25% of samples) 
were V36M, T54S, and R155K, with less common (in 5% 
to <25%) mutations including T54A, V55A, R155T, 
A156S, V158I, and V170A (data not shown). Infrequent 
mutations (in <5% of samples) included V36A, V36L, 
and I170T (data not shown).
Rapid virological response was highly associated with 
SVR in all treatment groups. In the 28-week treatment 
groups, 82% (54/66) of patients in the PR4/PRB24 group 
and 74% (32/43) in the PRB28 group who had rapid 
virological response achieved SVR. In the 48-week 
treatment groups, 94% (62/66) of patients assigned to 
PR4/PRB44 and 84% (32/38) assigned to PRB48 who 
achieved undetectable hepatitis C virus RNA by week 4 of 
boceprevir achieved SVR. Achievement of undetectable 
hepatitis C virus RNA between weeks 4 and 12 of 
boceprevir therapy was also highly predictive of SVR in 
the 48-week treatment groups (table 3; ﬁ gure 4). We 
noted a greater SVR in patients who cleared virus between 
weeks 4 and 12 of boceprevir in the PR4/PRB44 group 
compared with the PR4/PRB24 group (table 3).
The lead-in (PR4) allowed us to examine the relation 
of peginterferon and ribavirin responsiveness at week 4 
to SVR with boceprevir-containing regimens. In the 
PR4 28-week or 48-week groups, SVR was similar in 
participants with greater than 1·5 log10 reduction in 
hepatitis C virus RNA from baseline before the addition 
of boceprevir. Higher SVR was noted in participants 
who received PRB for 44 weeks with less than 1·5 log10 
reduction from baseline at PR4 (ﬁ gure 5). In patients 
Figure 3: Trial proﬁ le for part 2 of the study
PRB48=peginterferon alfa-2b, ribavirin, and boceprevir 800 mg three times 
a day for 48 weeks. Low-dose PRB48=peginterferon alfa-2b, ribavirin 
400–1000 mg, and boceprevir 800 mg three times a day for 48 weeks.
16 assigned to PRB48
16 treated
8 completed treatment phase
8 discontinued treatment
4 adverse event
4 protocol-deﬁned clinical event
0 lost to follow-up
0 did not wish to continue
0 non-compliance with protocol
14 entered follow-up
14 completed follow-up
0 discontinued follow-up
0 lost to follow-up
0 did not wish to continue
0 non-compliance with protocol
2 never entered follow-up
59 assigned to  low-dose PRB48
59 treated
28 completed treatment phase
31 discontinued treatment
7 adverse event
16 protocol-deﬁned clinical event
3 lost to follow-up
3 did not wish to continue
2 non-compliance with protocol
50 entered follow-up
41 completed follow-up
9 discontinued follow-up
5 lost to follow-up
1 did not wish to continue
3 non-compliance with protocol
9 never entered follow-up
75 treated
Part 1 Part 2
PR48 (n=104) PR4/PRB24 (n=103) PR4/PRB44 (n=103) PRB28 (n=107) PRB48 (n=103) PRB48 (n=16) Low-dose PRB48 (n=59)
Overall SVR (%; 95% CI)* 39 (38%; 28–48%) 58 (56%; 46–66%) 77 (75%; 65–83%) 58 (54%; 44–64%) 69 (67%; 57–76%) 8 (50%; 25–75%) 21 (36%; 24–49%)
Diﬀ erence from control (95% CI) .. 19% (5–32)† 37% (25–50)† 17% (3–30)‡ 29% (16–42)† .. ..
TW 4 8 (8%) 3 (3%) 9 (9%) 42 (39%) 38 (37%) 7 (44%) 15 (25%)
TW 8 22 (21%) 62 (60%) 66 (64%) 71 (66%) 64 (62%) 11 (69%) 24 (41%)
TW 12 35 (34%) 71 (69%) 79 (77%) 78 (73%) 70 (68%) 8 (50%) 32 (54%)
TW 24 54 (52%) 74 (72%) 82 (80%) 71 (66%) 71 (69%) 8 (50%) 28 (48%)
TW 48 48 (46%) NA 73 (71%) NA 60 (58%) 6 (38%) 25 (42%)
End of treatment§ 53 (51%) 79 (77%)† 81 (79%)† 84 (79%)† 76 (74%)† 9 (56%) 28 (48%)
Relapse rate¶ 12 (24%) 18 (24%) 2 (3%)† 24 (30%) 5 (7%)† 1 (11%) 6 (22%)
Viral breakthrough|| 0 4 (4%) 5 (5%) 7 (7%)† 12 (12%)† 4 (25%) 16 (27%)
Data are number (%) unless otherwise indicated. PR4 (lead-in)=peginterferon alfa-2b 1·5 μg/kg plus ribavirin 800−1400 mg per day for 4 weeks. PR48 (control)=peginterferon alfa-2b 1·5 μg/kg plus ribavirin 
800−1400 mg per day for 48 weeks. PRB24/28/44/48=peginterferon alfa-2b, ribavirin, and boceprevir 800 mg three times a day for 24, 28, 44, or 48 weeks. Low-dose PRB48=peginterferon alfa-2b, ribavirin 
400–1000 mg, and boceprevir 800 mg three times a day for 48 weeks. SVR=sustained virological response. TW=treatment week. NA=not available. *Patients who discontinued therapy before the end of their 
speciﬁ ed duration were followed up, and those with undetectable hepatitis C virus RNA at end of follow-up were counted as having achieved SVR. †Nominal p values<0·01 (treatment vs control) for end of 
treatment, SVR, and relapse and viral breakthrough in part 1. ‡Nominal p values<0·05 (treatment vs control) for end of treatment, SVR, and relapse and viral breakthrough in part 1. §Last dose of study drug. 
¶Relapse rate is deﬁ ned as the proportion of patients with detectable hepatitis C virus RNA at end of follow-up in patients who were undetectable at end of treatment and not missing follow-up data. Relapse 
rates in part 1 in those who cleared virus at week 4 of boceprevir therapy were 11% (95% CI 5–22) for PR4/PRB24, 2% (0–9) for PR4/PRB44, 21% (9–36) for PRB28, and 6% (1–20) for PRB48; and for part 2, 
0% (0–46) for PRB48 and 14% (2–43) for low-dose PRB48. ||Persistent ≥2 log10 increase from nadir and ≥50 000 IU/mL. 
Table 2: Virological response
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with less than 1 log10 reduction with PR4, 55% (95% CI 
32–76) SVR was noted in the PR4/PRB44 group.
A multivariate regression analysis of pooled boceprevir 
groups in part 1 of the study was done by investigation 
of baseline factors associated with SVR. These factors 
included low viral load (≤600 000 IU/mL), non-black 
race, lower platelet count, and genotype 1b. In the 
control group of this study which received the standard 
of care, black people and those with cirrhosis had a 
lower SVR than did participants of non-black race and 
with no cirrhosis (table 4). The SVR rate for black people 
in the PR48 control group was 13% (two of 16) and as 
high as 53% (eight of 15) in patients treated with 
boceprevir for 48 weeks (table 4). In patients with 
cirrhosis, the SVR rate was 67% (ten of 15) in the 
combined longer duration boceprevir groups versus 
25% (two of eight) in the control group; in patients 
without cirrhosis, the SVR rate for the combined longer 
duration boceprevir groups was 71% (136/191) compared 
with 39% (37/96) for the control group.
We also noted increased rates of SVR in patients who 
developed anaemia (haemoglobin <100 g/L) irrespective 
of treatment group. Epoetin alfa was used by 40% 
(236/595) of patients and was allowed at investigator 
discretion. The use of this drug in those with anaemia 
was also associated with an improved SVR (table 4).
The most common adverse events in the boceprevir 
groups, as reported by investigators, were fatigue, 
anaemia, nausea, and headache—a side-eﬀ ect proﬁ le 
generally similar to that recorded in patients receiving 
PR48 control. The rate of dysgeusia and anaemia was 
higher in the boceprevir groups than in other groups 
(table 5). In the boceprevir groups, we detected nadir 
haemoglobin concentrations of 85–100 g/L in those who 
developed anaemia; and haemoglobin concentrations 
less than 85 g/L were rare (table 6). Dose modiﬁ cations 
of ribavirin were similar in boceprevir groups compared 
with the PR48 control group, and boceprevir dose 
modiﬁ cations were rare (table 7). We recorded an overall 
higher discontinuation rate in the boceprevir groups 
than in the control group (table 7). Treatment 
discontinuations attributable to adverse events ranged 
from 9% to 19% in the groups receiving boceprevir 
therapy compared with 8% for the PR48 group, with two 
patients discontinuing treatment because of anaemia in 
the boceprevir groups (table 7). The rate of adverse events 
categorised as skin and subcutaneous tissue disorders 
was similar in boceprevir-containing regimens (159/416, 
38%) and the control group (38/104, 37%).
Discussion
The results of this phase 2 trial have shown that an 
optimum dose of boceprevir (800 mg three times a day), 
when added to the standard of care for treatment of 
chronic genotype 1 hepatitis C virus, signiﬁ cantly 
increased SVR in both 28-week and 48-week regimens 
compared with the control of peginterferon alfa-2b and 
ribavirin. Responses in the 48-week boceprevir groups 
were substantially higher than were those in the 28-week 
groups, with a near doubling of SVR in the PR4/PRB44 
group. The use of low-dose ribavirin in combination 
with peginterferon and boceprevir, while reducing 
haematological toxic eﬀ ects, did not improve SVR rates 
compared with control.
These results are consistent with those recorded in 
two trials of another NS3 protease inhibitor, telaprevir, 
in combination with peginterferon and ribavirin, in 
populations that excluded those with histological 
cirrhosis and had fewer black people.17,18 In one of these 
studies,17 undertaken in the USA, the SVR rate in the 
telaprevir group receiving 24 weeks of treatment with 
12 weeks of telaprevir and 24 weeks of peginterferon 
and ribavirin was 20% higher than in the control group 
of 48 weeks of peginterferon and ribavirin (61% [48/79] 
vs 41% [31/75]); and in the telaprevir group receiving 
48 weeks of treatment with 12 weeks of telaprevir added 
to 48 weeks of peginterferon and ribavirin, the SVR rate 
 PR48 
(n=104)
PR4/PRB24 
(n=103)
PR4/PRB44 
(n=103)
PRB28 
(n=107)
PRB48 
(n=103)
≤4 weeks* 100% (8/8) 82% (54/66) 94% (62/66) 74% (32/43) 84% (32/38) 
>4 week–≤12 weeks* 83% (24/29) 21% (4/19) 79% (15/19) 62% (26/42) 84% (36/43) 
>12 weeks* 30% (7/23) 0% (0/1) 0% (0/1) 0% (0/3) 17% (1/6) 
Never undetectable 0% (0/44) 0% (0/17) 0% (0/17) 0% (0/19) 0% (0/16) 
All participants 38% (39/104) 56% (58/103) 75% (77/103) 54% (58/107) 67% (69/103) 
Data are % (n/N). PR4 (lead-in)=peginterferon alfa-2b 1·5 μg/kg plus ribavirin 800−1400 mg per day for 4 weeks. 
PR48 (control)=peginterferon alfa-2b 1·5 μg/kg plus ribavirin 800−1400 mg per day for 48 weeks. 
PRB24/28/44/48=peginterferon alfa-2b, ribavirin, and boceprevir 800 mg three times a day for 24, 28, 44, or 
48 weeks. *Exposure to weeks of peginterferon alfa-2b and ribavirin for group 1 and to weeks of boceprevir for 
groups 2–5.
Table 3: Rates of sustained virological response by time to ﬁ rst undetectable hepatitis C virus RNA
Figure 4: Percentage of patients with undetectable hepatitis C virus (HCV) RNA over time
PR4 (lead-in)=peginterferon alfa-2b 1·5 μg/kg plus ribavirin 800−1400 mg per day for 4 weeks. 
PR48 (control)=peginterferon alfa-2b 1·5 μg/kg plus ribavirin 800−1400 mg per day for 48 weeks. 
PRB24/28/44/48=peginterferon alfa-2b, ribavirin, and boceprevir 800 mg three times a day for 24, 28, 44, or 
48 weeks.
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was 26% higher than it was in the 48-week control group 
(67% [53/79] vs 41% [31/75]). In the other study,18 
undertaken in Europe, the SVR rate in the telaprevir 
group receiving 24 weeks of treatment with 12 weeks of 
telaprevir and 24 weeks of peginterferon and ribavirin 
was 23% higher than in the 48-week control group (69% 
[56/81] vs 46% [38/82]). Although the study designs and 
populations diﬀ ered, in our study, SVR rates were 
17–19% higher than in the control group in the 28-week 
boceprevir group, and 29–37% higher than control in 
the 48-week boceprevir groups.
In black participants and in those with cirrhosis, the 
addition of boceprevir to standard of care improved SVR.
These preliminary results in a fairly small number of 
patients suggest that the addition of boceprevir to 
peginterferon alfa-2b and ribavirin will improve SVR in 
these diﬃ  cult-to-treat populations.
This study assessed the use of a PR4 lead-in before the 
addition of boceprevir, as well as the eﬀ ect of starting all 
three drugs concomitantly, and compared these groups 
with PR48 control. In the novel lead-in approach, we 
recorded increased SVR and a reduction in relapse and 
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Figure 5: Predictability of sustained virological response (SVR) on the basis of response during 4-week lead-in
Undetectable hepatitis C virus RNA with Roche COBAS TaqMan with lower limit of detection less than 15 IU/mL. Seven patients in 28-week groups and two in 48-week 
groups week missing week-4 virology. PR4 (lead-in)=peginterferon alfa-2b 1·5 μg/kg plus ribavirin 800–1400 mg per day for 4 weeks. PR48 (control)=peginterferon alfa-
2b 1·5 μg/kg plus ribavirin 800–1400 mg per day for 48 weeks. PRB24/44=peginterferon alfa-2b, ribavirin, and boceprevir 800 mg three times a day for 24 or 44 weeks.
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breakthrough, and allowed for potential determination of 
treatment duration on the basis of responsiveness to the 
PR4 lead-in. However, in the direct comparison between 
lead-in and non-lead-in groups, relapse reduction did not 
diﬀ er signiﬁ cantly, although the absence of a statistically 
conclusive result is not surprising since the sample size 
did not allow detection of modest diﬀ erences between 
lead-in and non-lead-in groups. The mutations recorded 
in participants with viral breakthrough were consistent 
what those that have been previously reported with NS3 
inhibitors with no new mutations noted.23–26 The clinical 
relevance of these mutations is unknown, and long-term 
follow-up is in progress.
The viral response during the lead-in could help to 
predict best possible treatment duration. Patients 
achieving less than 1·5 log10 reduction in viral level after 
PR4 beneﬁ t most from a treatment duration of 48 weeks, 
whereas those with greater than 1·5 log10 reduction show 
Part 1 OR (95% CI) for PR4/PRB44 
vs control (PR48)*
PR48 
(n=104)
PR4/PRB24
(n=103)
PR4/PRB44 
(n=103)
PRB28 
(n=107)
PRB48 
(n=103)
Overall  SVR 39 (38%) 58 (56%) 77 (75%) 58 (54%) 69 (67%) 5·4 (2·9–10·0)
Sex
Men 28/70 (40%) 33/51 (65%) 41/58 (71%) 33/63 (52%) 40/63 (64%) 4·0 (1·8–8·5)
Women 11/34 (32%) 25/52 (48%) 36/45 (80%) 25/44 (59%) 29/40 (73%) 8·7 (2·8–27·0)
Race†
Non-black 37/88 (42%) 52/88 (59%) 69/88 (78%) 51/89 (57%) 65/89 (73%) 5·3 (2·7–10·3)
Black 2/16 (13%) 6/15 (40%) 8/15 (53%) 7/18 (39%) 4/14 (29%) 14·9 (1·5–144·2)
HCV genotype†‡§
1a 16/53 (30%) 27/53 (51%) 43/60 (72%) 34/67 (51%) 32/55 (58%) 7·5 (3·1–18·2)
1b 17/42 (41%) 22/37 (60%) 29/35 (83%) 21/30 (70%) 30/36 (83%) 6·5 (2·2–19·5)
1 (no subtype) 6/9 (67%) 9/13 (69%) 5/8 (63%) 3/10 (30%) 7/12 (58%) 0·9 (0·1–9·3)
Liver histology
Cirrhosis 2/8 (25%) 4/7 (57%) 3/6 (50%) 4/7 (57%) 7/9 (78%) 5·0 (0·3–72·8)
No cirrhosis 37/96 (39%) 54/96 (56%) 74/97 (76%) 54/100 (54%) 62/94 (66%) 5·9 (3·0–11·4)
Fasting glucose (mmol/L)§
<5·6 28/69 (41%) 41/72 (57%) 53/71 (75%) 39/69 (57%) 44/62 (71%) 4·6 (2·2–9·8)
≥5·6 9/25 (36%) 15/25 (60%) 19/22 (86%) 12/26 (46%) 16/30 (53%) 14·1 (2·5–79·9)
Baseline HCV-RNA†
>600 000 IU/mL 30/93 (32%) 48/89 (54%) 67/92 (73%) 52/99 (53%) 63/94 (67%) 6·2 (3.2–12·1)
≤600 000 IU/mL 9/11 (89%) 10/14 (71%) 10/11 (91%) 6/8 (75%) 6/9 (67%) 2·7 (0·2–42·7)
Baseline platelet count (×1000)†§¶
<169·5 5/19 (26%) 4/11 (36%) 9/15 (60%) 7/15 (47%) 12/16 (75%) 32/57 (56%)||
169·5–<237·4 14/44 (32%) 25/42 (60%) 33/41 (80%) 32/49 (65%) 26/38 (68%) 116/170 (68%)||
237·4–<305·4 12/26 (46%) 23/33 (70%) 28/33 (85%) 12/27 (44%) 22/34 (65%) 85/127 (67%)||
≥305·4 8/15 (53%) 6/17 (35%) 7/14 (50%) 7/16 (44%) 9/15 (60%) 29/62 (47%)||
Nadir haemoglobin (g/L)
≥100 27/78 (35%) 24/51 (47%) 35/55 (64%) 23/49 (47%) 31/55 (56%) ..
<100 12/25 (48%) 34/51 (67%) 42/48 (88%) 35/57 (61%) 38/48 (79%) ..
Epoetin alfa use
Yes 9/27 (33%) 33/50 (66%) 46/53 (87%) 27/48 (56%) 32/40 (80%) ..
No 30/77 (39%) 25/53 (47%) 31/50 (62%) 31/59 (53%) 37/63 (59%) ..
PR4 (lead-in)=peginterferon alfa-2b 1·5 μg/kg plus ribavirin 800−1400 mg per day for 4 weeks. PR48 (control)=peginterferon alfa-2b 1·5 μg/kg plus ribavirin 800−1400 mg 
per day for 48 weeks. PRB24/28/44/48=peginterferon alfa-2b, ribavirin, and boceprevir 800 mg three times a day for 24, 28, 44, or 48 weeks. OR=odds ratio. SVR=sustained 
virological response. HCV=hepatitis C virus. *For each baseline subgroup, the odds ratio and 95% CI for treatment eﬀ ect (PR4/PRB44 vs PR48) are based on logistic 
regression model with adjustment for stratiﬁ cation factors (race and cirrhosis status). †Signiﬁ cant predictor of SVR based on multivariable logistic regression analysis (all 
boceprevir-containing groups combined): race (non-black vs black;  OR 2·7, 95% CI 1·49–5·04); genotype (1b vs 1a/other; 2·0, 1·22–3·32); baseline viral load (low vs high; 
2·3, 1·04–5·12); and standardised baseline platelet count (continuous; 0·8, 0·61–0·94). ‡Viral genotype was measured with the TruGene assay (Bayer HealthCare, Berkeley, 
CA, USA). §Analyses of the relations between SVR and hepatitis C virus genotype, fasting glucose, and baseline platelet count were not preplanned. ¶Baseline platelet count 
included in multivariable logistic regression analysis as a continuous variable, standardised by transforming each patient’s count as: (count–overall mean)/(overall SD). 
SVR rates are provided as descriptive statistics for platelet count intervals based on mean and SD: 169·5=1 SD below mean; 237·4=mean; 305·4=1 SD above mean. ||Data are 
number (%) for pooled boceprevir groups.
Table 4: Factors aﬀ ecting sustained virological response
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similar SVR irrespective of treatment duration of 
28 weeks or 48 weeks. The lead-in can identify null 
responders to peginterferon alfa-2b and ribavirin, who 
seem to be at greatest risk for treatment failure with 
speciﬁ cally targeted therapies and for development of 
resistance. However, in our cohort, a substantial proportion 
of null responders during the lead-in period went on to 
achieve SVR with the addition of boceprevir.16,27
In all groups, rapid virological response was highly 
predictive of SVR. We also recorded high rates of rapid 
virological response in the 48-week treatment groups. 
Participants who cleared virus between weeks 4 and 12 of 
boceprevir therapy were more likely to go on to SVR if 
they received 48 weeks of treatment rather than 28 weeks. 
Thus, in the treatment of genotype 1 hepatitis C virus, 
nearly two-thirds of patients achieved undetectable 
hepatitis C virus RNA levels at week 4 of boceprevir 
therapy after PR4, and these individuals can be treated for 
28 weeks with high SVR. Of the additional 18% (19/103) 
of patients who go on to achieve undetectable hepatitis C 
virus RNA between weeks 4 and 12 of boceprevir therapy, 
79% (15/19) of patients beneﬁ t from extending therapy 
with peginterferon alfa-2b, ribavirin, and boceprevir to 
48 weeks. Only one patient in the boceprevir groups who 
developed undetectable hepatitis C virus RNA after 
week 12 of boceprevir therapy went on to SVR.
We noted no new adverse events or treatment-limiting 
toxic eﬀ ects associated with boceprevir-containing 
regimens in this trial compared with those recorded in 
patients receiving peginterferon and ribavirin. No 
increases in skin or subcutaneous adverse events were 
noted in the boceprevir-containing groups compared with 
the control groups. Higher rates of both anaemia and 
dysgeusia were noted in the boceprevir-containing 
regimens than in the control group, although stopping 
treatment for anaemia was rare. Haemoglobin reductions 
in the PRB48 low-dose group were less than those in the 
control group and in any of the full-dose PRB groups in 
part 1, and similar to the haemoglobin reduction in the 
PR48 group of part 1 of the study. In this study, use of 
epoetin alfa was allowed at the investigator’s discretion 
and was associated with improved SVR. A study suggested 
that development of anaemia with haemoglobin less than 
100 g/L is associated with increased SVR in patients 
receiving pegylated interferon and ribavirin; anaemia is 
potentially a surrogate marker of increased ribavirin 
concentration and the addition of epoetin alfa might allow 
patients to remain on therapy.28 In our study, the 
development of anaemia and the use of epoetin alfa were 
associated with improved SVR in the boceprevir-containing 
regimens. However, since there was no randomisation for 
use of epoetin alfa in this study, the contributions of 
anaemia and epoetin alfa use to improved SVR with 
boceprevir remains to be established. The role of epoetin 
alfa as an adjuvant in patients receiving pegylated 
interferon and ribavirin in addition to therapy with direct-
acting antiviral agents deserves further study. We recorded 
a higher drop-out rate in the boceprevir-containing groups 
than in the control group, as has been noted when other 
direct-acting antiviral agents are added to peginterferon 
Part 1 Part 2
PR48 
(n=104)
PR4/PRB24 
(n=103)
PR4/PRB44 
(n=103)
PRB28 
(n=107)
PRB48 
(n=103)
PRB48 
(n=16)
Low-dose 
PRB48 
(n=59)
Fatigue 57 (55%) 70 (68%) 73 (71%) 65 (61%) 51 (50%) 11 (69%) 40 (68%)
Anaemia 35 (34%) 55 (53%) 58 (56%) 60 (56%) 54 (52%) 10 (63%) 14 (24%)
Headache 45 (43%) 41 (40%) 54 (52%) 52 (49%) 44 (43%) 13 (81%) 29 (49%)
Nausea 45 (43%) 42 (41%) 48 (47%) 41 (38%) 56 (54%) 10 (63%) 35 (59%)
Insomnia 40 (38%) 29 (28%) 41 (40%) 36 (34%) 40 (39%) 7 (44%) 23 (39%)
Pyrexia 35 (34%) 27 (26%) 35 (34%) 28 (26%) 41 (40%) 7 (44%) 26 (44%)
Chills 35 (34%) 31 (30%) 35 (34%) 31 (29%) 33 (32%) 5 (31%) 26 (44%)
Alopecia 27 (26%) 30 (29%) 35 (34%) 36 (34%) 30 (29%) 5 (31%) 19 (32%)
Diarrhoea 23 (22%) 27 (26%) 29 (28%) 28 (26%) 25 (24%) 5 (31%) 14 (24%)
Dysgeusia 9 (9%) 27 (26%) 28 (27%) 23 (21%) 33 (32%) 7 (44%) 18 (31%)
Neutropenia 12 (12%) 17 (17%) 31 (30%) 25 (23%) 26 (25%) 3 (19%) 19 (32%)
Inﬂ uenza-like illness 25 (24%) 21 (20%) 15 (15%) 24 (22%) 19 (18%) 6 (38%) 11 (19%)
Arthralgia 21 (20%) 22 (21%) 19 (18%) 14 (13%) 21 (20%) 5 (31%) 11 (19%)
Dizziness 16 (15%) 16 (16%) 14 (14%) 19 (18%) 21 (20%) 7 (44%) 11 (19%)
Vomiting 5 (5%) 15 (15%) 17 (17%) 24 (22%) 25 (24%) 7 (44%) 11 (19%)
Decreased appetite 12 (12%) 14 (14%) 12 (12%) 7 (7%) 17 (17%) 6 (38%) 16 (27%)
Injection-site reaction 10 (10%) 5 (5%) 11 (11%) 9 (8%) 9 (9%) 4 (25%) 21 (36%)
Data are number (%). Adverse events as assessed and reported by investigator are presented in decreasing frequency on the 
basis of the counts for all treatments combined. PR4 (lead-in)=peginterferon alfa-2b 1·5 μg/kg plus ribavirin 800−1400 mg 
per day for 4 weeks. PR48 (control)=peginterferon alfa-2b 1·5 μg/kg plus ribavirin 800−1400 mg per day for 48 weeks. 
PRB24/28/44/48=peginterferon alfa-2b, ribavirin, and boceprevir 800 mg three times a day for 24, 28, 44, or 48 weeks. 
Low-dose PRB48=peginterferon alfa-2b, ribavirin 400–1000 mg, and boceprevir 800 mg three times a day for 48 weeks.
Table 5: Adverse events during treatment (≥30% incidence)
Part 1 Part 2
PR48 
(n=104)
PR4/PRB24 
(n=103)
PR4/PRB44 
(n=103)
PRB28 
(n=107)
PRB48 
(n=103)
PRB48 
(n=16)
Low-dose 
PRB48 (n=59)
Neutrophils (cells per μL)
500–<750 15 (15%) 13 (13%) 22 (21%) 22 (21%) 33 (32%) 0 12 (20%)
<500 3 (3%) 8 (8%) 15 (15%) 14 (13%) 5 (5%) 2 (14%) 0
Haemoglobin (g/L)
85–<100 25 (24%) 50 (49%) 43 (42%) 52 (49%) 45 (44%) 7 (50%) 12 (20%)
<85 0 1 (1%) 5 (5%) 5 (5%) 3 (3%) 2 (14%) 0
Epoetin alfa use 53 (51%) 50 (49%) 40 (39%) 27 (26%) 48 (45%) 9 (56%) 9 (15%)
pRBC transfusion 0 1 (1%) 0 0 0 0 1 (<1%)
Platelets (×109/L)
25–<50 0 2 (2%) 3 (3%) 4 (4%) 1 (1%) 0 1 (2%)
<25 0 0 1 (1%) 0 0 0 0
Data are number (%). Haematological parameters during therapy are reported. Reduction of dose of peginterferon was 
recommended if neutrophil count was less than 0·75×10⁹/L and/or platelet count was less than 50×10⁹/L; 
discontinuation of peginterferon was recommended if neutrophil count was less than 0·5×10⁹/L and/or platelet count 
was less than 25×10⁹/L. Reduction of ribavirin dose was recommended if haemoglobin was less than 100 g/L, and 
discontinuation or interruption of ribavirin occurred if haemoglobin was less than 85 g/L. PR4 (lead-in)=peginterferon 
alfa-2b 1·5 μg/kg plus ribavirin 800−1400 mg per day for 4 weeks. PR48 (control)=peginterferon alfa-2b 1·5 μg/kg 
plus ribavirin 800−1400 mg per day for 48 weeks. PRB24/28/44/48=peginterferon alfa-2b, ribavirin, and boceprevir 
800 mg three times a day for 24, 28, 44, or 48 weeks. Low-dose PRB48=peginterferon alfa-2b, ribavirin 
400–1000 mg, and boceprevir 800 mg three times a day for 48 weeks. pRBC=packed red blood cells.
Table 6: Haematological parameters
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alfa-2b and ribavirin.17 This ﬁ ndings suggests that treating 
physicians might need experience with these agents to 
ensure patient adherence and manage side-eﬀ ects, as was 
noted with the introduction of ribavirin to interferon 
therapy for hepatitis C virus infection.17,18
There are potential limitations of this study which 
deserve mention. This was an open-label study with regard 
to the administration of boceprevir because of the complex 
study design with comparisons of lead-in and non-lead-in 
groups, and diﬀ ering treatment durations. However, all 
assays were done by an independent commercial 
laboratory that did not have access to participant treatment 
assignments. The primary and other key study endpoints 
were based on hepatitis C virus RNA level—an outcome 
that is not subject to bias. Another possible limitation 
concerns the stratiﬁ cation of patients as with or without 
cirrhosis. We required a liver biopsy sample to be taken 
within 5 years of enrolment into the study. A patient who 
tested negative for cirrhosis 5 years before the beginning 
of the study could have developed cirrhosis in the 
intervening years. Thus patients with cirrhosis could have 
been mischaracterised as being non-cirrhotic, biasing the 
results in favour of the population with this disease. 
Therefore, the promising results obtained in patients with 
cirrhosis who received boceprevir will need conﬁ rmation 
in larger trials that are in progress.
In conclusion, boceprevir, in combination with pegylated 
interferon and ribavirin, achieved high SVR rates with 
28 weeks of therapy in most patients and is safe and 
eﬀ ective for use up to 48 weeks in the few patients who 
beneﬁ t from longer duration of therapy. We also recorded 
increased response rates in diﬃ  cult-to-treat groups, 
including black participants and those with cirrhosis. The 
use of PR4 lead-in before the addition of boceprevir 
improves SVR over a 48-week duration, and reduces viral 
breakthrough and relapse. A large conﬁ rmatory trial is in 
progress and will deﬁ ne the best treatment regimen for 
the use of boceprevir in the treatment of genotype 1 chronic 
hepatitis C virus infection.
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Part 1 Part 2
PR48 
(n=104)
PR4/PRB24 
(n=103)
PR4/PRB44 
(n=103)
PRB28 
(n=107)
PRB48 
(n=103)
PRB48 
(n=16)
Low-dose PRB48 
(n=59)
Overall discontinuations 16 (15%) 27 (26%) 27 (26%) 30 (28%) 40 (39%) 8 (50%) 31(53%)
p value compared with PR48 (control) .. 0·055 0·055 0·026 0·0001 .. ..
Reason for discontinuation
Adverse event 8 (8%) 15 (15%) 9 (9%) 12 (11%) 20 (19%) 4 (25%) 7 (12%)
Serious adverse event 3 (3%) 6 (6%) 3 (3%) 6 (6%) 9 (9%) 1 (6%) 0
Anaemia* 0 1 0 0 0 1 0
Dose reductions due to adverse events
All 30 (29%) 57 (55%) 66 (64%) 56 (52%) 58 (56%) 8 (50%) 15 (25%)
Reductions of peginterferon and/or ribavirin only† 30 (29%) 49 (48%) 50 (49%) 46 (43%) 41 (40%) 8 (50%) 14 (24%)
Reductions due to boceprevir‡ 0 8 (8%) 16 (16%) 10 (9%) 17 (17%) 0 1 (2%)
Data are number (%) unless otherwise indicated. Reduction of dose of peginterferon was recommended if neutrophil count was less than 0·75×10⁹/L and/or platelet count was 
less than 50×10⁹/L; discontinuation of peginterferon was recommended if neutrophil count was less than 0·5×10⁹/L and/or platelet count was less than 25×10⁹/L. Reduction of 
ribavirin dose was recommended if haemoglobin was less than 100 g/L and discontinuation or interruption of ribavirin occurred if haemoglobin was less than 85 g/L. PR4 
(lead-in)=peginterferon alfa-2b 1·5 μg/kg plus ribavirin 800−1400 mg per day for 4 weeks. PR48 (control)=peginterferon alfa-2b 1·5 μg/kg plus ribavirin 800−1400 mg per day for 
48 weeks. PRB24/28/44/48=peginterferon alfa-2b, ribavirin, and boceprevir 800 mg three times a day for 24, 28, 44, or 48 weeks. Low-dose PRB48=peginterferon alfa-2b, ribavirin 
400–1000 mg, and boceprevir 800 mg three times a day for 48 weeks. *Two patients discontinued because of clinically relevant anaemia. †Includes reductions of peginterferon only, 
ribavirin only, and both peginterferon and ribavirin. ‡Includes reductions of boceprevir only and reductions of boceprevir along with peginterferon and/or ribavirin.
Table 7: Discontinuations and dose reductions
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